An August 2026 draft report by ICER found that new aldosterone synthase inhibitor hypertension drugs cost between $833,000 and $2.08 million per quality-adjusted life year gained compared with generic alternatives.

Drug pricing and affordability, FDA drug approvals, clinical trial design, drug shortages, insurer coverage, pharmaceutical regulation, and medication access.

Drug pricing policy, insurance prior authorization, and essential drug shortages affecting medication affordability and access.

Generic drug approval, biosimilar development, and their impact on drug affordability.